Insulet SEC Filings

Type
Report
Date
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/12/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/4/2026
4Insidertransaktion3/3/2026
4Insidertransaktion3/3/2026
4Insidertransaktion3/3/2026
4Insidertransaktion3/3/2026
4Insidertransaktion3/3/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
4Insidertransaktion2/26/2026
8-K/A8-K/A-Formular2/24/2026
4Insidertransaktion2/23/2026
10-KJahresbericht2/18/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/18/2026
4Insidertransaktion2/17/2026
4Insidertransaktion2/17/2026
4Insidertransaktion2/17/2026
4Insidertransaktion2/17/2026
4Insidertransaktion2/17/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/5/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/3/2026
4Insidertransaktion1/6/2026
4Insidertransaktion1/6/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/19/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/17/2025
4Insidertransaktion12/16/2025
144144-Formular12/15/2025
4Insidertransaktion12/8/2025
144144-Formular11/26/2025
144144-Formular11/24/2025
10-QQuartalsbericht11/6/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/6/2025
4Insidertransaktion11/3/2025
33-Formular11/3/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular10/30/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/23/2025
4Insidertransaktion10/2/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/16/2025
144144-Formular9/16/2025
4Insidertransaktion9/9/2025
4Insidertransaktion9/9/2025
144144-Formular9/8/2025
144144-Formular9/8/2025
4Insidertransaktion8/22/2025
4Insidertransaktion8/21/2025
144144-Formular8/21/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/13/2025
4Insidertransaktion8/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/7/2025
10-QQuartalsbericht8/7/2025
144144-Formular8/7/2025
4Insidertransaktion8/5/2025
33-Formular7/29/2025
4Insidertransaktion6/16/2025
4Insidertransaktion6/16/2025
144144-Formular6/13/2025
144144-Formular6/13/2025
4Insidertransaktion6/10/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/9/2025
144144-Formular6/9/2025
SDSD-Formular5/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/28/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
4Insidertransaktion5/27/2025
S-8S-8-Formular5/22/2025
144144-Formular5/16/2025
4Insidertransaktion5/15/2025
4Insidertransaktion5/15/2025
4Insidertransaktion5/14/2025
4Insidertransaktion5/14/2025
144144-Formular5/14/2025
144144-Formular5/13/2025
144144-Formular5/13/2025
144144-Formular5/13/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/13/2025
10-QQuartalsbericht5/9/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2025
4Insidertransaktion5/5/2025
33-Formular5/2/2025
4Insidertransaktion4/30/2025
DEF 14ADEF 14A-Formular4/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/28/2025
8-K/A8-K/A-Formular4/9/2025
4Insidertransaktion3/26/2025
144144-Formular3/25/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/21/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/18/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/18/2025

Insulet Documents 2026

This page contains all official documents and SEC filings for Insulet stock (PODD, ISIN: US45784P1012). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Insulet's regulatory filings.

Insulet Stock analysis

Insulet Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future.